Zoetis Inc (ZTS) Stake Increased by CGOV Asset Management
CGOV Asset Management boosted its stake in Zoetis Inc (NYSE:ZTS) by 2.7% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 169,605 shares of the company’s stock after buying an additional 4,405 shares during the period. Zoetis accounts for about 0.4% of CGOV Asset Management’s holdings, making the stock its 24th largest position. CGOV Asset Management’s holdings in Zoetis were worth $12,059,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. First Manhattan Co. boosted its position in shares of Zoetis by 50.8% in the third quarter. First Manhattan Co. now owns 8,740 shares of the company’s stock valued at $454,000 after buying an additional 2,945 shares during the last quarter. Shinko Asset Management Co. Ltd. raised its stake in Zoetis by 289.5% in the third quarter. Shinko Asset Management Co. Ltd. now owns 4,709 shares of the company’s stock worth $245,000 after buying an additional 3,500 shares during the period. YHB Investment Advisors Inc. raised its stake in Zoetis by 3.4% in the third quarter. YHB Investment Advisors Inc. now owns 24,635 shares of the company’s stock worth $1,281,000 after buying an additional 805 shares during the period. California Public Employees Retirement System raised its stake in Zoetis by 2.5% in the third quarter. California Public Employees Retirement System now owns 1,351,200 shares of the company’s stock worth $70,276,000 after buying an additional 32,600 shares during the period. Finally, Sanders Morris Harris Inc. raised its stake in Zoetis by 137.9% in the third quarter. Sanders Morris Harris Inc. now owns 116,850 shares of the company’s stock worth $6,077,000 after buying an additional 67,725 shares during the period. Institutional investors own 94.54% of the company’s stock.
Zoetis Inc (NYSE:ZTS) traded down 0.32% during trading on Tuesday, hitting $53.33. 695,571 shares of the stock were exchanged. The stock has a market cap of $26.24 billion, a price-to-earnings ratio of 32.32 and a beta of 1.07. Zoetis Inc has a 1-year low of $45.28 and a 1-year high of $56.50. The firm’s 50 day moving average price is $53.45 and its 200-day moving average price is $52.46.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 16th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.45 by $0.02. Zoetis had a return on equity of 72.96% and a net margin of 14.10%. The business earned $1.30 billion during the quarter, compared to analyst estimates of $1.28 billion. During the same period in the previous year, the firm earned $0.43 EPS. Zoetis’s quarterly revenue was up .2% compared to the same quarter last year. On average, analysts anticipate that Zoetis Inc will post $2.32 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 1st. Investors of record on Thursday, April 6th will be given a $0.105 dividend. The ex-dividend date is Tuesday, April 4th. This represents a $0.42 annualized dividend and a dividend yield of 0.79%. Zoetis’s dividend payout ratio is presently 30.44%.
A number of analysts have recently issued reports on the stock. Guggenheim increased their price target on shares of Zoetis from $60.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, February 16th. Jefferies Group LLC reissued a “buy” rating and issued a $62.00 price target on shares of Zoetis in a research report on Tuesday, December 20th. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $60.00 price target for the company in a research report on Thursday, December 29th. BMO Capital Markets reissued an “outperform” rating and issued a $59.00 price target on shares of Zoetis in a research report on Friday, December 23rd. Finally, Deutsche Bank AG began coverage on shares of Zoetis in a research report on Tuesday, December 20th. They issued a “buy” rating and a $62.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Zoetis presently has an average rating of “Hold” and an average price target of $57.12.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc and related companies with MarketBeat.com's FREE daily email newsletter.